iOnctura, headquartered in Geneva, was founded in June 2017 as a spin out from Merck KGaA. It is a clinical stage biotechnology company developing a pipeline of next generation, best in class molecules that are at the forefront of pioneering new therapies for the treatment of cancer. iOnctura has a pipeline of carefully selected assets licensed from Merck and Cancer Research UK. Its programs in oncology aim to harness both immune-mediated and direct anti-tumour activity to deliver superior clinical efficacy in monotherapy or combinations. By building on complementary mechanisms between cancer and fibrosis, iOnctura further aims to address high unmet need in fibrotic disease.